16 min read
Keypoint Newsletter: May 2025
Welcome to the Keypoint Newsletter, bringing you all the latest news & views from Keystone Symposia!
Featuring...
David Soto-Pantoja, PhD, investigates cell surface receptor CD47 as an immunotherapy for breast, lung, head and neck cancers and melanoma. Through clinical trials and animal model collaborations, he explores the effects of CD47 targeting on tumor cell bioenergetics, with the goal of developing anti-cancer therapeutics that inhibit tumor growth and prevent chemotherapy-related cardiac toxicity.
Research Area(s):
Research Keywords:
Mentor: Juanita L. Merchant, MD, PhD
May 6, 2025 by Shannon Weiman
Featuring...
Apr 23, 2025 by Shannon Weiman
Our April Fellow's Spotlight goes to Dr. Vivien Maltez, PhD, an Assistant Professor in the Division of Allergy,...